St. Jude Children's Research Hospital, Inc.
Patent owner in reexamination·5 ex parte reexams
St. Jude Children's Research Hospital, Inc.'s patents have been the subject of 5 USPTO ex parte reexaminations. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
118
119
321
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (5)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/014,883 | Oct 15, 2021 | 10,829,737 | Chimeric Receptor with NKG2D Specificity for Use in Cell Therapy Against Cancer and Infectious Disease | — | Closed |
| 90/014,882 | Oct 15, 2021 | 10,774,309 | Natural killer cell immunotherapy for treating cancer | — | Closed |
| 90/014,779 | Jun 21, 2021 | 9,511,092 | A Chimeric Receptor With NKG2D Specificity For Use In Cell Therapy Against Cancer And Infectious Disease | — | Closed |
| 90/014,353 | Aug 2, 2019 | 9,511,092 | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE | — | Closed |
| 90/014,175 | Aug 1, 2018 | 9,511,092 | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE | — | Closed |
See the full reexam picture for St. Jude Children's Research Hospital, Inc.
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.